Cross-reactive neutralizing activity in HIV-1 infected injecting drug users

por Euler, Z, van Gils, MJ, Schuitemaker, H
Publicado 2012

P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression

por Dispinseri, S, Cavarelli, M, van Nuenen, A, Schuitemaker, H, Scarlatti, G
Publicado 2009

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression

por van Gils, MJ, Euler, Z, Schweighardt, B, Wrin, T, Schuitemaker, H
Publicado 2009

P09-14. Emergence of b12 resistant rapidly replication HIV-1 variants during natural infection in the absence of humoral or cellular immune pressure

por Bunnik, E, Lobbrecht, M, Pisas, L, van Nuenen, A, Schuitemaker, H
Publicado 2009

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level

por Bunnik, EM, Euler, Z, Welkers, M, Grijsen, M, Prins, J, Schuitemaker, H
Publicado 2009

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals

por van den Kerkhof, TL, Euler, Z, van Gils, MJ, Boeser-Nunnink, BD, Verwer, NL, Schuitemaker, H, Sanders, RW
Publicado 2012

Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations

por Salisch, N. C., Izquierdo Gil, A., Czapska-Casey, D. N., Vorthoren, L., Serroyen, J., Tolboom, J., Saeland, E., Schuitemaker, H., Zahn, R. C.
Publicado 2019

OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles

por Schellens, IM, Navis, M, van Deutekom, HW, Boeser-Nunnink, B, Berkhout, B, Kootstra, N, Miedema, F, Kesmir, C, Schuitemaker, H, van Baarle, D, Borghans, JA
Publicado 2009

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization

por Heyndrickx, L, Stewart-Jones, G, Schuitemaker, H, Bowles, E, Buonaguro, L, Jansson, M, Grevstad, B, Vinner, L, Ramaswamy, M, Biswas, P, Scarlatti, G, Vanham, G, Fomsgaard, A
Publicado 2012

P19-20. Allogeneic stimulation of the anti-viral APOBEC3G in human CD4+ T cells and prevention of SHIV infectivity in macaques immunized with HLA antigens

por Wang, Y, Whittall, T, Scholler, J, Wyatt, R, Singh, M, Bergmeier, LA, Bunnik, E, Schuitemaker, H, Shaw, O, Vaughan, R, Pido-Lopez, J, Seidl, T, Babaahmady, K, Yang, G, Thorstensson, R, Biberfeld, G, Lehner, T
Publicado 2009

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group

por Scarlatti, G, Alcami, J, Bongertz, V, Fenyö, E, Heath, A, Heyndrickx, L, Holmes, H, Jansson, M, Lopalco, L, Malnati, M, Montefiori, D, Moog, C, Morris, L, Osmanov, S, Polonis, V, Ramaswamy, M, Sattentau, Q, Schuitemaker, H, Wrin, T
Publicado 2009

P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques

por Mörner, A, Schøller, J, Bunnik, E, Jansson, M, Wehlin, L, Bergqvist, L, Pihlainen, E Hansson, Shaw, O, Seidl, T, Wang, Y, Bergmeier, LA, Singh, M, Vaughan, R, Yang, G, Shao, Y, Wyatt, RT, Schuitemaker, H, Biberfeld, G, Thorstensson, R, Lehner, T
Publicado 2009